Suppr超能文献

癌症和姑息治疗环境中医院焦虑和抑郁量表(HADS)的诊断有效性:荟萃分析。

Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis.

机构信息

Department of Cancer and Molecular Medicine, Leicester Royal Infirmary, University of Leicester LE1 5WW, United Kingdom.

出版信息

J Affect Disord. 2010 Nov;126(3):335-48. doi: 10.1016/j.jad.2010.01.067. Epub 2010 Mar 5.

Abstract

OBJECTIVE

To examine the validity of the Hospital Anxiety and Depression Scale (HADS) in the identification of psychiatric complications of cancer, as defined by a robust criterion standard.

METHODS

50 analyses tested the depression subscale (HADS-D), anxiety subscale (HADS-A) or combined scales (HADS-T) against syndromal (clinical) depression (n=22), syndromal anxiety (n=4) or any mental ill health/distress (n=24), all defined by semi-structured psychiatric interview.

RESULTS

The HADS and its subscales had both strengths and limitations. Overall it appeared to perform marginally better in non-palliative cancer settings. Specific findings for each subscale were as follows. In the identification of depression the HADS-T, HADS-D and HADS-A had a pooled sensitivity and specificity of 82.0%, 77.0%; 71.6%, 82.6% and 80.5%, 77.8%, respectively. All versions performed poorly in case-finding but well in a screening capacity. For anxiety there were no HADS-D studies. The HADS-T and HADS-A had a pooled sensitivity and specificity of 83.9%, 69.9% and 48.7%, 78.7%. They were poor at case-finding but good as screening instruments. For distress (any mental ill health) the HADS-T, HADS-D and HADS-A had a pooled sensitivity and specificity of 72.8%, 80.6%; 75.7%, 66.3% and 65.7%, 71.3%, respectively. When screening for distress and anxiety the HADS-T was the optimal subscale.

CONCLUSION

For the identification of depression, anxiety or distress in cancer settings, the HADS (including subscales) is not recommended as a case-finding instrument but it may, subject to concerns about its length, be a suitable addition to screening programme.

摘要

目的

通过使用可靠的标准来检验医院焦虑抑郁量表(HADS)识别癌症患者精神并发症的有效性。

方法

共进行了 50 项分析,通过对 22 例综合征性(临床)抑郁症、4 例综合征性焦虑症或 24 例任何心理健康/痛苦(通过半结构化精神病学访谈定义)患者,分别使用抑郁量表(HADS-D)、焦虑量表(HADS-A)或综合量表(HADS-T)进行测试。

结果

HADS 及其子量表都有优点和局限性。总体而言,它在非姑息性癌症环境中表现略好。各子量表的具体发现如下。在识别抑郁症方面,HADS-T、HADS-D 和 HADS-A 的合并敏感性和特异性分别为 82.0%和 77.0%、71.6%和 82.6%、80.5%和 77.8%。所有版本在病例发现方面表现不佳,但在筛查能力方面表现良好。焦虑症方面没有 HADS-D 的研究。HADS-T 和 HADS-A 的合并敏感性和特异性分别为 83.9%和 69.9%、48.7%和 78.7%。它们在病例发现方面表现不佳,但作为筛查工具表现良好。对于痛苦(任何心理健康不佳),HADS-T、HADS-D 和 HADS-A 的合并敏感性和特异性分别为 72.8%和 80.6%、75.7%和 66.3%、65.7%和 71.3%。在筛查痛苦和焦虑时,HADS-T 是最佳的子量表。

结论

对于癌症患者中抑郁、焦虑或痛苦的识别,不建议将 HADS(包括子量表)作为病例发现工具,但考虑到其长度问题,它可能适合加入到筛查项目中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验